Chitosan: A potential polymer for colon-specific drug delivery system

Expert Opinion on Drug Delivery

Volumn 9, Issue 6, 2012, Pages 713-729

  Gulbake, Arvind ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Chitosan; Colon delivery; Colon targeting; Oral delivery

Indexed keywords

6 CARBOXYFLUORESCEIN; ACECLOFENAC; AMINOLEVULINIC ACID; ANTISENSE OLIGONUCLEOTIDE; BUDESONIDE; CAFFEINE; CELECOXIB; CHITOSAN; DILTIAZEM; DNA; ELCATONIN; EUDRAGIT; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MESALAZINE; MICROSPHERE; NANOPARTICLE; ONDANSETRON; OVALBUMIN; OXALIPLATIN; PACLITAXEL; POLYMER; PREBIOTIC AGENT; PREDNISOLONE; REBAMIPIDE; RETINOIC ACID; UNINDEXED DRUG; VALDECOXIB; VANCOMYCIN;

BIOCOMPATIBILITY; BIODEGRADATION; COLON; COLON CROHN DISEASE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; CROSS LINKING; DEACETYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG TARGETING; EPITHELIUM CELL; GENE TARGETING; HUMAN; HYDROGEL; IRRITABLE COLON; MOLECULAR WEIGHT; MUCOADHESION; NONHUMAN; PH; PHYSICAL CHEMISTRY; REVIEW; SUSTAINED DRUG RELEASE; TABLET; ULCERATIVE COLITIS;

BIOLOGICAL AVAILABILITY; CHITOSAN; COLON; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; SOLUBILITY;

EID: 84861309314     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.682148     Document Type: Review

References (142)

1. Rouget C. Starchy substances in the tissues of animals, especially of Articulated (chitin). C R Acad Sci Ser III 1859;48:792-5
2. Wadhwa S, Paliwal R, Paliwal SR, et al. Chitosan and its role in ocular therapeutics. Mini Rev Med Chem 2009;9(14):1639-47
3. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release 2003;89:151-65 (Pubitemid 36507012)
4. Mina BM, Leeb SW, Limb JN, et al. Chitin and chitosan nanofibers: electrospinning of chitin and deacetylation of chitin nanofibers. Polymer 2004;45:7137-42
5. Prashanth KVH, Tharanathan RN. Chitin/chitosan: modifications and their unlimited application potential: an overview. Trend Food Sci Tech 2007;18:117-31 (Pubitemid 46329341)
6. Rha CK, Rodriguez-Sanchez D, Kienzle-Sterzer C. Novel applications of chitosan. In: Colwell RR, Pariser ER, Sinskey AJ, editors. Biotechnology of Marine Polysaccharides. Hemisphere; Washington: 1984. p. 284-311
7. Struszczyk H, Wawro D, Niekraszewicz A. Biodegradability of chitosan fibres. In: Brine CJ, Sandford PA, Zikakis JP, editors. Advances in Chitin and Chitosan. Elsevier Applied Science; London: 1991. p. 580-5
8. Roberts GAF. Solubility and solution behaviour of chitin and chitosan. In: Roberts GAF, editor. Chitin Chemistry. MacMillan; Houndmills: 1992. p. 274-329
9. Felt O, Furrer P, Mayer JM, et al. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm 1999;180:185-93 (Pubitemid 29238202)
10. Hirano S. Chitin biotechnology applications. Biotechnol Annu Rev 1996;2:237-58
11. Tiyaboonchai W. Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ J 2003;11:51-66
12. Chung YC, Fang C, Fung C. Preparation and characterization of water-soluble chitosan produced by Maillard reaction. Fisheries Sci 2006;72:1096-103 (Pubitemid 44453735)
13. Park SY, Marsh KS, Rhim JW. Characteristics of different molecular weight chitosan films affected by the type of organic solvents. J Food Sci 2002;67:194-8
14. Tang ESK, Huang M, Lim LY. Ultrasonication of chitosan and chitosan nanoparticles. Int J Pharm 2003;265:103-14 (Pubitemid 37176951)
15. Huang M, Fongb CW, Khorc E, et al. Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J Control Release 2005;106:391-406 (Pubitemid 41187448)
16. Miyazaki S, Nakayama A, Oda M, et al. Attwood D. Drug release from oral mucosal adhesive tablets of chitosan and sodium alginate. Int J Pharm 1995;118:257-63
17. Lopez CR, Portero A, Vila-Jato JL, et al. Design and evaluation of chitosan/ ethylcellulose mucoadhesive bilayered devices for buccal drug delivery. J Control Release 1998;55:143-52 (Pubitemid 28477605)
18. Gaserød O, Jolliffe AG, Hampson FC, et al. The enhancement of the bioadhesive properties of calcium alginate gel beads by coating with chitosan. Int J Pharm 1998;175:237-46 (Pubitemid 28517980)
19. Lopez CR, Portero A, Lemos M, et al. Chitosan microspheres for the specific delivery of amoxycillin to the gastric cavity. STP Pharm Sci 2000;10:69-76 (Pubitemid 30126788)
20. Lehr CM, Bouwstra JA, Schacht EH, et al. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992;78:43-8
21. He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm 1998;166:75-88 (Pubitemid 28239741)
22. Tozaki H, Komoike J, Tada C, et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997;86:1016-21 (Pubitemid 27382903)
23. Jain SK, Jain A, Gupta Y, et al. Design and development of hydrogel beads for targeted drug delivery to the colon. AAPS PharmSciTech 2007;8:E56
24. Jain SK, Jain A, Gupta Y, et al. Targeted delivery of 5-ASA to colon using chitosan hydrogel microspheres. J Drug Deliv Sci Tech 2008;18(5):315-21
25. Shahidi F, Arachchi JKV, Jeon YJ. Food applications of chitin and chitosans. Trends Food Sci Technol 1999;10:37-51 (Pubitemid 29306025)
26. Kanauchi O, Deuchi K, Imasato Y, et al. Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate. Biosci Biotechnol Biochem 1995;59:786-90
27. Wuolijoki E, Hirvela T, Ylitalo P. Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp Clin Pharmacol 1999;21:357-61 (Pubitemid 29291252)
28. Muzzarelli RAA. Human enzymatic activities related to the therapeutic administration of chitin derivatives. Cell Mol Life Sci 1997;53:131-40 (Pubitemid 27365884)
29. Koga D. Chitin enzymology - chitinase. In: Chen R, Chen HC, editors. Adv Chitin Sci 1998;3:16-23
30. Muzzarelli R, Baldassare V, Conti F, et al. Biological activity of chitosan: ultrastructure study. Biomaterials 1988;9:247-52
31. Hsu SC, Don TM, Chiu WY. Free radical degradation of chitosan with potassium persulfate. Polym Degrad Stab 2002;75:73-83
32. Zoldners J, Kiseleva T, Kaiminsh I. Influence of ascorbic acid on the stability of chitosan solutions. Carbohydr Polym 2005;60:215-18 (Pubitemid 40480078)
33. Kanehisa Laboratories. KEGG Amino sugar and nucleotide sugar metabolism reference pathway. EUROGENE portal 2009
34. Kean T, Thanou M. Chitin and chitosan - sources, production and medical applications. In: Williams PA, Arshady R, editors. Desk reference of Natural Polymers, their Sources, Chemistry and Applications. Kentus Books; London: 2009. p. 327-61
35. Yang YM, Hu W, Wang XD, et al. The controlling biodegradation of chitosan fibers by n-acetylation in vitro and in vivo. J Mater Sci Mater Med 2007;18:2117-21 (Pubitemid 350167374)
36. Xu J, McCarthy SP, Gross RA, et al. Chitosan film acylation and effects on biodegradability. Macromolecules 1996;29:3436-40 (Pubitemid 126542285)
37. Boot RG, Blommaart EF, Swart E, et al. Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 2001;276:6770-8
38. Chourasia MK, Jain SK. Design and development of multiparticulate system for targeted drug delivery to colon. Drug Deliv 2004;11:201-7 (Pubitemid 38720417)
39. Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv 2004;11:129-48 (Pubitemid 38437082)
40. Jain SK, Jain A. Target-specific drug release to the colon. Expert Opin Drug Deliv 2008;5:483-98 (Pubitemid 351877430)
41. Walker WA, lsselbacher KJ. Uptake and transport of macromolecules by the intestine. Gastroenterology 1974;67:531-50
42. Brady PG, Vannicr AM Banwell JG. Identification of the dietary lectin, wheat germ agglutinin, in human intestinal contents. Gastroenterology 1978;75:236-9 (Pubitemid 8372293)
43. Stevens CE. Comparative physiology of the digestive system. Chapter 18. In: Swenson MJ, editor. Physiology of Domestic Animals. Cornell University Press; Ithaca, NY: 1977
44. Edwards C. Physiology of the colorectal barrier. Adv Drug Deliv Rev 1997;28:173-90 (Pubitemid 28078665)
45. Friend DR. Colon-specific drug delivery. Adv Drug Deliv Rev 1991;7:149-99
46. Washington N, Washington C, Wilson CG. Physiological Pharmaceutics Barriers to Drug Absorption Drug Delivery to the Large Intestine and Rectum. 2nd edition. Taylor and Francis, London; 2003
47. Lee VHL, Mukherjee SK. Drug Delivery: Oral Colon-Specific. Encyclopedia of Pharmaceutical Technology. 3rd edition. Informa Healthcare, USA, New York: 2006. p. 1228-41
48. Nigalaye AG, Adusumili P, Bolton S. Investigation of prolonged drug release from matrix formulations of chitosan. Drug Dev Ind Pharm 1990;16(3):449-67 (Pubitemid 20027636)
49. Adusumili P, Bolton S. Evaluation of chitosan citrate complexes as matrices for controlled release formulation. Drug Dev Ind Pharm 1990;17(14):1931-45
50. Sawayanagi Y, Nambu N, Nagai T. Direct compressed tablets containing chitin or chitosan in addition to lactose or potato starch. Chem Pharm Bull 1982;30(8):2935-40 (Pubitemid 13235417)
51. Sawayanagi Y, Nambu N, Nagai T. Direct compressed tablets containing chitin. Chem Pharm Bull 1982b;30(11):4216-18
52. Knapczyk J. Excipient ability of chitosan for direct tableting. Int J Pharm 1993;89:1-7 (Pubitemid 23008582)
53. Ritthidej GC, Chomto P, Pummanggura S. Chitin and chitosan as disintegrants in paracetamol tablets. Drug Dev Ind Pharm 1990;19(8):915-27
54. Upadrashta SM, Katikaneni PR, Nuessle NO. Chitosan as a tablet binder. Drug Dev Ind Pharm 1992;18(15):2701-8
55. Miyazaki S. Chitin and chitosan as vehicle for drug delivery. Zairyo Gijutsu 1998;16:276
56. Aiedeh K, Taha MO. Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered, colon-specific drug delivery systems. Arch Pharm (Weinheim) 1999;332(3):103-7 (Pubitemid 29162586)
57. Amrutkar JR, Gattani SG. Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin. AAPS PharmSciTech 2009;10(2):670-7
58. Nunthanida J, Laungtana-anana M, Sriamornsaka P, et al. Characterization of chitosan acetate as a binder for sustained release tablets. J Control Release 2004;99:15-26
59. Huanbutta K, Sriamornsak P, Limmatvapirat S, et al. Swelling kinetics of spray-dried chitosan acetate assessed by magnetic resonance imaging and their relation to drug release kinetics of chitosan matrix tablets. Eur JPharm Biopharm 2011;77:320-6
60. Macleod GS, Collett JH, Fell JT. The potential use of mixed films of pectin, chitosan and HPMC for bimodal drug release. J Control Release 1999;58(3):303-10 (Pubitemid 29142454)
61. Kaur G, Jain S, Tiwary AK. Chitosan-carboxymethyl tamarind kernel powder interpolymer complexation: investigations for colon drug delivery. Sci Pharm 2010;78(1):57-78
62. Tozaki H, Fujita T, Odoriba T, et al. Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J Pharm Pharmacol 1999; 51:1107-12 (Pubitemid 29520456)
63. Tozaki H, Odoriba T, Okada N, et al. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release 2002;82:51-61 (Pubitemid 34775047)
64. Tozaki H, Fujita T, Odoriba T, et al. Colon specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. Life Sci 1999;64:1155-62 (Pubitemid 29152033)
65. Fetih G, Lindberg S, Itoh K, et al. Improvement of absorption enhancing effects of n-dodecyl-beta-Dmaltopyranoside by its colon-specific delivery using chitosan capsules. Int J Pharm 2005;293(1-2):127-35 (Pubitemid 40381086)
66. Huang BB, Li GF, Luo JH, et al. Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier. World J Gastroenterol 2008;14(31):4928-37
67. Fetih G, Fausia H, Okada N, et al. Colon-specific delivery and enhanced colonic absorption of [Asu(1,7)]-eel calcitonin using chitosan capsules containing various additives in rats. J Drug Target 2006;14(3):165-72 (Pubitemid 43878825)
68. Pavanetto F, Perugini P, Conti B, et al. Evaluation of process parameters involved in chitosan microspheres. J Microencapsul 1996;13(6):679-88
69. Kas HS. Chitosan: properties, preparation and application to microparticulate systems. J Microencaps 1997;14:689-711 (Pubitemid 27483088)
70. Yabe H, Itoyama M, Kawamura Y. Manufacture of chitosan and chitin porous microparticles. JP632210101A2; 1988
71. Yamanami T, Tsuchida S, Seki M. Preparation of chitosan powder for pharmaceutics. JP63017902A2; 1988
72. Aydin Z, Akbuga J. Chitosan beads for the delivery of salmon calcitonin: preparation and release characteristics. Int J Pharm 1996;131:101-3 (Pubitemid 26143833)
73. Aral C, Akbuga J. Alternative approach to the preparation of chitosan beads. Int J Pharm 1998;168:9-15 (Pubitemid 28293658)
74. McPhail D, Tetley L, Dufes C, et al. Liposomes encapsulating polymeric chitosan based vesicles - a vesicle in vesicle system for drug delivery. Int J Pharm 2000;200:73-86 (Pubitemid 30177252)
75. Murata Y, Toniwa S, Miyamoto E, et al. Preparation of alginate gel beads containing chitosan salt and their function. Int J Pharm 1999;176:265-8 (Pubitemid 29048311)
76. Berthold A, Cremer K, Kreuter J. Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J Control Release 1996a;39:17-25 (Pubitemid 26139808)
77. Berthold A, Cremer K, Kreuter J. Influence of crosslinking on the acid stability and physicochemical properties of chitosan microspheres. STP Pharm Sci 1996b;6:358-64
78. Genta I, Constantini IM, Conti AAB, et al. Influence of glutardialdehyde on drug release and mucoadhesive properties of chitosan microspheres. Carbohydr Polym 2000;36:81-8
79. Carreno-Gomez B, Duncan R. Evaluation of biological properties of soluble chitosan and chitosan microspheres. Int J Pharm 1997;148:231-40 (Pubitemid 27160980)
80. Lorenzo-Lamosa M, Remunan-Lopez C, Vila-Jato JL. Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release 1998;52:109-18 (Pubitemid 28123178)
81. Tominaga S, Takaizawa T, Yamada M. Colon drug delivery system. J Pol Appl 1998; JP 10 324, 642 (98324,642) (C1 A61K47/36)
82. Mladenovska K, Raicki RS, Janevik EI, et al. Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. Int J Pharm 2007;342:124-36 (Pubitemid 47259341)
83. Xu Y, Zhan C, Fan L, et al. Preparation of dual crosslinked alginate chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery system. Int J Pharm 2007;336(2):329-37 (Pubitemid 46670661)
84. Srinatha A, Pandit JK. Alternate polyelectrolyte coating of chitosan beads for extending drug release. Drug Deliv 2008;15(3):193-9 (Pubitemid 351465719)
85. Ohya Y, Shiratani M, Kobayashi H, et al. Release behavior of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity. Pure Appl Chem 1994;A31:629-42
86. Calvo P, Remunan-Lopez C, Vila-Jato JL, et al. Chitosan and chitosan/ethylene oxidepropylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997;14:1431-6 (Pubitemid 27481075)
87. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan based micro-and nanoparticles in drug delivery. J Control Release 2004;100:5-28 (Pubitemid 39445982)
88. Elzatahry AA, Eldin MSM. Preparation and characterization of metronidazole loaded chitosan nanoparticles for drug delivery application. Polym Adv Technol 2008;19:1787-91
89. Jain A, Jain SK. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur JPharm Sci 2008;35(5):404-16
90. Li P, Wang Y, Zeng F, et al. Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells. Carbohydr Res 2011;1:346(6):801-6
91. Venkatesan P, Puvvada N, Dash R, et al. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials 2011;32(15):3794-806
92. Tahara K, Samura S, Tsuji K, et al. Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide- coglycolide) nanospheres for inflammatory bowel disease. Biomaterials 2011;32(3):870-8
93. Kost J, Langer R. In: Peppas NA. editor. Hydrogels in Medicine and Pharmacy. CRC Press; Boca Raton: 1987. p. 95
94. Graham NB. Controlled drug delivery systems. Chem Ind 1990;15:482
95. Hari PR, Chandy T, Sharma CP. Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin. J Microencapsul 1996;13:319-29 (Pubitemid 26149541)
96. Bernkop-Schnurch A. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int J Pharm 2000;194:1-13
97. Sinha VR, Kumria R. Binders for colon specific drug delivery: an in vitro evaluation. Int J Pharm 2002;249:23-31 (Pubitemid 35333429)
98. Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5:387-91 (Pubitemid 29180575)
99. Zhou XH. Overcoming enzymatic and absorption barriers to nonparenterally administered protein and peptide drugs. J Control Release 1994;29:239-52
100. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug 1994;11:61-95
101. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186-9 (Pubitemid 24259861)
102. Artursson P, Lindmark T, Davis SS, et al. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358-61 (Pubitemid 24287420)
103. Schipper NGM, Olsson S, Hoogstraate JA, et al. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res 1997;14:923-9 (Pubitemid 27326989)
104. Kotze AF, de Leeuw BJ, Luegen HL, et al. Chitosan for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers. Int J Pharm 1997;159:243-53 (Pubitemid 28055860)
105. Lueßen HL, Rentel CO, Kotze AF, et al. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J Control Release 1997;45:15-23 (Pubitemid 27055788)
106. Orienti I, Cerchiara T, Luppi B, et al. Influence of different chitosan salts on the release of sodium diclofenac in colon-specific delivery. Int J Pharm 2002;238:51-9 (Pubitemid 34457875)
107. Borchard G, Luegen HL, de Boer AG, et al. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption: III. Effects of chitosan glutamate and carbomer on epithelial tight junctions in vitro. J Control Release 1996;39:131-8 (Pubitemid 26194212)
108. Schipper NGM, Varum KM, Stenberg P, et al. Chitosans as absorption enhancers of poorly absorbable drugs 3: influence of mucus on absorption enhancement. Eur J Pharm Sci 1999;8:335-43 (Pubitemid 29325026)
109. Mumper RJ, Wang J, Claspell JM, et al. Novel polymeric condensing carriers for gene delivery. Proc Intern Symp Control Release Bioact Mater 1995;22:178-9
110. Mao HQ, Roy K, Walsh SM, et al. DNA-chitosan nanospheres for gene delivery. Proc Intern Symp Control Release Bioact Mater 1996;23:401-2 (Pubitemid 26294118)
111. Jayakumar R, Chennazhi KP, Muzzarelli RAA, et al. Chitosan conjugated DNA nanoparticles in gene therapy. Carbohydr Polym 2010;79:1-8
112. Tahara KS, Yamamoto H, Hirashima N, et al. Chitosan-modified poly(D,Llactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur JPharm Biopharm 2010;74:421-6
113. Lee DW, Yun KS, Ban HS, et al. Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release 2009;139:146-52
114. Nielsen EJ, Nielsen JM, Becker D, et al. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/ siRNA nanoparticles. Pharm Res 2010;27(12):2520-7
115. Behrens I, Pena AI, Alonso MJ, et al. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res 2002;19:1185-93 (Pubitemid 34985003)
116. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 2002;19:1488-94 (Pubitemid 35266553)
117. Dodane V, Khan MA, Merwin JR. Effect of chitosan on transepithelial permeability and epithelial morphology. Mol Biol Cell 1996;7:608
118. Meza I, Ibarra G, Sabanero M, et al. Occluding junctions and cytoskeletal components in a cultured transporting epithelium. J Cell Biol 1980;87:746-54 (Pubitemid 11161806)
119. Koch MA, Dodane V, Khan MA, et al. Chitosan induced effects on epithelial morphology as seen by confocal scanning microscopy. Scanning 1998;20:262-3 (Pubitemid 128496050)
120. Omwancha W, Kouba C, Yelamanchili S, et al. Colon-specific drug delivery using ethylcellulose and chitosan in the coat of compression-coated tablets. Drug Dev Ind Pharm 2011;37(8):945-53
121. Yassin AE, Alsarra IA, Alanazi FK, et al. New targeted-colon delivery system: in vitro and in vivo evaluation using X-ray imaging. J Drug Target 2010;18(1):59-66
122. Kaur G, Rana V, Jain S, et al. Colon delivery of budesonide: evaluation of chitosan-chondroitin sulfate interpolymer complex. AAPS Pharm Sci Tech 2010;11(1):36-45
123. Quinteros DA, Manzo RH, Allemandi DA. Design of a colonic delivery system based on cationic polymethacrylate (Eudragit E100)-mesalamine complexes. Drug Deliv 2010;17(4):208-13
124. Bigucci F, Luppi B, Cerchiara T, et al. Chitosan/pectin polyelectrolyte complexes: selection of suitable preparative conditions for colon-specific delivery of vancomycin. Eur J Pharm Sci 2008;35(5):435-41
125. Yamamoto A. Study on the colon specific delivery of prednisolone using chitosan capsules. Yakugaku Zasshi 2007;127(4):621-30 (Pubitemid 46536535)
126. Jose S, Prema MT, Chacko AJ, et al. Colon specific chitosan microspheres for chronotherapy of chronic stable angina. Colloids Surf B Biointerfaces 2011;83(2):277-83
127. Umadevi SK, Thiruganesh R, Suresh S, et al. Formulation and evaluation of chitosan microspheres of aceclofenac for colon-targeted drug delivery. Biopharm Drug Dispos 2010;31(7):407-27
128. Dubey R, Dubey R, Omrey P, et al. Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis. J Drug Target 2010;18(8):589-601
129. Jose S, Dhanya K, Cinu TA, et al. Multiparticulate system for colon targeted delivery of ondansetron. Indian JPharm Sci 2010;72(1):58-64
130. Thakral NK, Ray AR, Majumdar DK. Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. J Mater Sci Mater Med 2010;21(9):2691-9
131. Chavarri M, Maranon I, Ares R, et al. Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules improves survival in simulated gastro-intestinal conditions. Int JFood Microbiol 2010;142(1-2):185-9
132. Maculotti K, Tira EM, Sonaggere M, et al. In vitro evaluation of chondroitin sulphate-chitosan microspheres as carrier for the delivery of proteins. J Microencapsul 2009;26(6):535-43
133. Glavas Dodov M, Calis S, Crcarevska MS, et al. Wheat germ agglutinin-conjugated chitosan-Ca-alginate microparticles for local colon delivery of 5-FU: development and in vitro characterization. Int J Pharm 2009;381(2):166-75
134. Crcarevska MS, Dodov MG, Petrusevska G, et al. Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis. J Drug Target 2009;17(10):788-802
135. Saboktakin MR, Tabatabaie RM, Maharramov A, et al. Synthesis and in vitro evaluation of carboxymethyl starch-chitosan nanoparticles as drug delivery system to the colon. Int JBiol Macromol 2011;48(3):381-5
136. Akhlaghi SP, Saremi S, Ostad SN, et al. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine 2010;6(5):689-97
137. Zuo L, Huang Z, Dong L, et al. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 2010;59(4):470-9
138. Kadiyala I, Loo Y, Roy K, et al. Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur JPharm Sci 2010;39(1-3):103-9
139. Jain A, Jain SK, Ganesh N, et al. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine 2010;6(1):179-90
140. Yang SJ, Shieh MJ, Lin FH, et al. Colorectal cancer cell detection by 5-aminolaevulinic acid-loaded chitosan nano-particles. Cancer Lett 2009;273(2):210-20
141. Bayat A, Dorkoosh FA, Dehpour AR, et al. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm 2008;356(1-2):259-66
142. Park JS, Koh YS, Bang JY, et al. Antitumor effect of all-trans retinoic acid-encapsulated nanoparticles of methoxy poly(ethylene glycol)-conjugated chitosan against CT-26 colon carcinoma in vitro. J Pharm Sci 2008;97(9):4011-19